OTC Markets OTCPK - Delayed Quote USD

Telesis Bio, Inc. (TBIO)

0.0500

0.0000

(0.00%)

At close: June 5 at 8:00:00 PM EDT

Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities

The strategic move is aimed at integrating automated, high-throughput gene synthesis into Regeneron's in-house laboratories.

Pharmaceutical Technology 10 days ago

REGN

TBIO
0.00%
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

SAN DIEGO, May 28, 2025--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio’s revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs.

Business Wire 11 days ago

TBIO
0.00%
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

SAN DIEGO, March 18, 2025--Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to

Business Wire 2 months ago

TBIO
0.00%
Telesis Bio: Q3 Earnings Snapshot

SAN DIEGO (AP) — Telesis Bio, Inc. TBIO) on Thursday reported a loss of $6.6 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of $4.09.

Associated Press Finance 6 months ago

TBIO
0.00%
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry CapabilitiesSAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio’s Gibson SOLA enzymatic reagent platform running on Beckman C

GlobeNewswire 8 months ago

TBIO
0.00%
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.001 per share (the “Common Stock”) and deregister t

GlobeNewswire 8 months ago

TBIO
0.00%
Telesis Bio: Q2 Earnings Snapshot

SAN DIEGO (AP) — Telesis Bio, Inc. TBIO) on Wednesday reported a loss of $12.6 million in its second quarter. On a per-share basis, the San Diego-based company said it had a loss of $7.62.

Associated Press Finance 9 months ago

TBIO
0.00%
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high

GlobeNewswire 9 months ago

TBIO
0.00%

Performance Overview

Return	TBIO	S&P 500 (^GSPC)
YTD	-87.50%	+2.02%
1-Year	-98.68%	+12.09%
3-Year	-99.92%	+45.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Telesis Bio, Inc. (TBIO)

Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

Telesis Bio: Q3 Earnings Snapshot

Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

Telesis Bio: Q2 Earnings Snapshot

Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

Performance Overview